Cargando…

Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies

The synucleinopathies Parkinson’s disease (PD) and Multiple system atrophy (MSA) — characterized by α-synuclein intracytoplasmic inclusions into, respectively, neurons and oligodendrocytes — are associated with impairment of the autophagy-lysosomal pathways (ALP). Increased expression of the master...

Descripción completa

Detalles Bibliográficos
Autores principales: Arotcarena, Marie-Laure, Bourdenx, Mathieu, Dutheil, Nathalie, Thiolat, Marie-Laure, Doudnikoff, Evelyne, Dovero, Sandra, Ballabio, Andrea, Fernagut, Pierre-Olivier, Meissner, Wassilios G., Bezard, Erwan, Dehay, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777809/
https://www.ncbi.nlm.nih.gov/pubmed/31434803
http://dx.doi.org/10.1172/jci.insight.129719
_version_ 1783456671911116800
author Arotcarena, Marie-Laure
Bourdenx, Mathieu
Dutheil, Nathalie
Thiolat, Marie-Laure
Doudnikoff, Evelyne
Dovero, Sandra
Ballabio, Andrea
Fernagut, Pierre-Olivier
Meissner, Wassilios G.
Bezard, Erwan
Dehay, Benjamin
author_facet Arotcarena, Marie-Laure
Bourdenx, Mathieu
Dutheil, Nathalie
Thiolat, Marie-Laure
Doudnikoff, Evelyne
Dovero, Sandra
Ballabio, Andrea
Fernagut, Pierre-Olivier
Meissner, Wassilios G.
Bezard, Erwan
Dehay, Benjamin
author_sort Arotcarena, Marie-Laure
collection PubMed
description The synucleinopathies Parkinson’s disease (PD) and Multiple system atrophy (MSA) — characterized by α-synuclein intracytoplasmic inclusions into, respectively, neurons and oligodendrocytes — are associated with impairment of the autophagy-lysosomal pathways (ALP). Increased expression of the master regulator of ALP, transcription factor EB (TFEB), is hypothesized to promote the clearance of WT α-synuclein and survival of dopaminergic neurons. Here, we explore the efficacy of targeted TFEB overexpression either in neurons or oligodendrocytes to reduce the pathological burden of α-synuclein in a PD rat model and a MSA mouse model. While TFEB neuronal expression was sufficient to prevent neurodegeneration in the PD model, we show that only TFEB oligodendroglial overexpression leads to neuroprotective effects in the MSA model. These beneficial effects were associated with a decreased accumulation of α-synuclein into oligodendrocytes through recovery of the ALP machinery. Our study demonstrates that the cell type where α-synuclein aggregates dictates the target of TFEB overexpression in order to be protective, paving the way for adapted therapies.
format Online
Article
Text
id pubmed-6777809
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-67778092019-10-10 Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies Arotcarena, Marie-Laure Bourdenx, Mathieu Dutheil, Nathalie Thiolat, Marie-Laure Doudnikoff, Evelyne Dovero, Sandra Ballabio, Andrea Fernagut, Pierre-Olivier Meissner, Wassilios G. Bezard, Erwan Dehay, Benjamin JCI Insight Research Article The synucleinopathies Parkinson’s disease (PD) and Multiple system atrophy (MSA) — characterized by α-synuclein intracytoplasmic inclusions into, respectively, neurons and oligodendrocytes — are associated with impairment of the autophagy-lysosomal pathways (ALP). Increased expression of the master regulator of ALP, transcription factor EB (TFEB), is hypothesized to promote the clearance of WT α-synuclein and survival of dopaminergic neurons. Here, we explore the efficacy of targeted TFEB overexpression either in neurons or oligodendrocytes to reduce the pathological burden of α-synuclein in a PD rat model and a MSA mouse model. While TFEB neuronal expression was sufficient to prevent neurodegeneration in the PD model, we show that only TFEB oligodendroglial overexpression leads to neuroprotective effects in the MSA model. These beneficial effects were associated with a decreased accumulation of α-synuclein into oligodendrocytes through recovery of the ALP machinery. Our study demonstrates that the cell type where α-synuclein aggregates dictates the target of TFEB overexpression in order to be protective, paving the way for adapted therapies. American Society for Clinical Investigation 2019-08-22 /pmc/articles/PMC6777809/ /pubmed/31434803 http://dx.doi.org/10.1172/jci.insight.129719 Text en © 2019 Arotcarena et al. http://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Arotcarena, Marie-Laure
Bourdenx, Mathieu
Dutheil, Nathalie
Thiolat, Marie-Laure
Doudnikoff, Evelyne
Dovero, Sandra
Ballabio, Andrea
Fernagut, Pierre-Olivier
Meissner, Wassilios G.
Bezard, Erwan
Dehay, Benjamin
Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies
title Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies
title_full Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies
title_fullStr Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies
title_full_unstemmed Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies
title_short Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies
title_sort transcription factor eb overexpression prevents neurodegeneration in experimental synucleinopathies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777809/
https://www.ncbi.nlm.nih.gov/pubmed/31434803
http://dx.doi.org/10.1172/jci.insight.129719
work_keys_str_mv AT arotcarenamarielaure transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies
AT bourdenxmathieu transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies
AT dutheilnathalie transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies
AT thiolatmarielaure transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies
AT doudnikoffevelyne transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies
AT doverosandra transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies
AT ballabioandrea transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies
AT fernagutpierreolivier transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies
AT meissnerwassiliosg transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies
AT bezarderwan transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies
AT dehaybenjamin transcriptionfactoreboverexpressionpreventsneurodegenerationinexperimentalsynucleinopathies